



Florida/Caribbean AIDS Education and Training Center

HIV CareLink

A Newsletter for HIV/AIDS Primary Care Providers

ABOUT US

The Florida/Caribbean AIDS Education and Training Center provides state-of-the-art HIV education, consultation, and resource materials to health care providers in Florida, Puerto Rico and the US Virgin Islands.

Major funding is provided by the US Public Health Service's Health Resources Services Administration (HRSA) DHHS-HAB Grant No. H4AHA00049 through the University of South Florida Center for HIV Education and Research, Michael Knox, PhD, Director.

EDITORS

Jeffrey Beal, MD, AAHIVS (239) 839-4645
aetcbear@embarqmail.com

Joanne J. Orrick, PharmD, AAHIVE (352) 273-7845
orricj@ufl.edu

PEDIATRIC EDITOR

Belinda Beauchamp, MD (787) 281-8501
bbeauchamp@rcm.upr.edu

MANAGING EDITOR

Kimberly Alfonso, MAcc (813) 974-4430
alfonso@fmhi.usf.edu

Volume 10 - Issue 6

April 21, 2009

Conference Update: The 16th Conference on Retroviruses and Opportunistic Infections (CROI 2009)

February 8-11, 2009

Montreal, Canada



Jeffrey Beal, MD, AAHIVS

Clinical Director, Florida/Caribbean AIDS Education and Training Center
Medical Director, Bureau of HIV/AIDS of the Florida Department of Health
Associate Professor, University of South Florida

Medical Director, Ryan White Part C, Hendry/Glades County Health Departments

The 16th Conference on Retroviruses and Opportunistic Infections (CROI 2009) took place in Montreal, Canada February 8-11, 2009. Below is a list of selected HIV-related abstract presentations from this conference along with a link to the abstract and poster on the CROI conference website (<http://www.retroconference.org/2009>)

Existing Antiretrovirals

- Switching from Stable Lopinavir/Ritonavir-based to Raltegravir-based Combination ART Resulted in a Superior Lipid Profile at Week 12 but Did Not Demonstrate Non-Inferior Virologic Efficacy at Week 24 ([Abstract 70aLB](#); [Eron, J, et al.](#))
- Switch from Enfuvirtide to Raltegravir in Highly Treatment-experienced HIV-1-infected Patients: A Randomized Open-Label Non-Inferiority Trial, Easier--ANRS 138 ([Abstract 572](#); [De Castro, N, et al.](#))
- Subgroup Analyses from STARTMRK, a Phase III Study of Raltegravir-based vs Efavirenz-based Combination Therapy in Treatment-naïve HIV-infected Patients ([Abstract 573](#); [Lennox, J, et al.](#))
- Lopinavir/ritonavir+Tenofovir/Emtricitabine Is Superior to Nevirapine+Tenofovir/Emtricitabine for Women with prior Exposure to Single-dose Nevirapine: A5208 ("OCTANE") ([Abstract 94LB](#); [Lockmann, S, et al.](#))

Immune Therapies

- Effect of Interleukin-2 on Clinical Outcomes in Patients with a CD4+ Cell Count of 300/mm³: Primary Results of the ESPRIT Study ([Abstract 90aLB](#); [Loso, M, et al.](#))
- Effect of Interleukin-2 on Clinical Outcomes in Patients with CD4+ Cell Count 50 to 299/mm³: Primary Results of the SILCAAT Study ([Abstract 90bLB](#); [Levy, Y, et al.](#))

Treatment Initiation

- Initiating rather than Deferring HAART at a CD4⁺ Count >500 Cells/mm³ Is Associated with Improved Survival ([Abstract 71](#); [Kitahata, M, et al.](#))
- When Should HIV-1-infected Persons Initiate ART? Collaborative Analysis of HIV Cohort Studies ([Abstract 72LB](#); [Sterne, J, et al.](#))

Resistance

- 96-Week Results from BENCHMRK 1 and 2, Phase III Studies of Raltegravir in Patients Failing ART with Triple-class-resistant HIV ([Abstract 571b](#); [Steigbigel, R, et al.](#))
- The Evolution of Classical Resistance to Emtricitabine Occurs at Rates Lower than Lamivudine, and May Be Regulated by Mutations Different than M184V ([Abstract 642](#); [Svicher, V, et al.](#))
- Drug Resistance Monitoring Practices Are Strongly Associated with Mortality ([Abstract 666](#); [Lima, V, et al.](#))
- CCR5-tropic Resistance to Maraviroc Is Uncommon even among Patients on Functional Maraviroc Monotherapy or with Ongoing Low-level Replication ([Abstract 639](#); [Jubb, B, et al.](#))
- Treatment Limitations Imposed by ARV Resistance Mutations: A Comparison of Initial Regimens Containing Boosted PI with Those Containing NNRTI ([Abstract 647](#); [Mtambo, A, et al.](#))

The complete collection of previous issues of HIV CareLink are available online.

To view past issues, please visit the archives at:

www.FCAETC.org/Newsletter

New Drugs

- Weekly and Biweekly Subcutaneous PRO 140 Demonstrates Potent, Sustained Antiviral Activity ([Abstract 571a](#); [Thompson, M, et al.](#))
- GS-9350: A Pharmacoenhancer without Anti-HIV Activity ([Abstract 40](#); [Mathias, A, et al.](#))
- Preclinical and Early Clinical Evaluation of SPI-452, a New Pharmacokinetic Enhancer ([Abstract 41](#); [Gulnik, S, et al.](#))
- Resistance-selection Study *in vitro* and Favorable Human Pharmacokinetic Properties of RDEA427, a New HIV NNRTI ([Abstract 569](#); [Ong, V, et al.](#))

Complications of ART

- Switching from Stable Lopinavir/Ritonavir-based to Raltegravir-based Combination Antiretroviral Therapy Resulted in a Superior Lipid Profile at Week 12 but Did Not Demonstrate Non-Inferior Virologic Efficacy at Week 24 ([Abstract 70aLB](#); [Eron, J, et al.](#))
- A Pilot Study to Determine the Effect on Dyslipidemia of the Addition of Tenofovir to Stable Background ART in HIV-infected Subjects: Results from the A5206 Study Team ([Abstract 714](#); [Tungsiripat, M, et al.](#))
- Risk of Extensive Triple-class Virologic Failure of the 3 Original ARV Drug Classes among People followed from Therapy Initiation with NNRTI or Ritonavir-boosted Protease Inhibitor Regimens ([Abstract 585](#); [Lodwick, R, et al.](#))
- Impact of Specific NRTI and PI Exposure on the Risk of Myocardial Infarction: A Case-Control Study Nested within FHDH ANRS CO4 ([Abstract 43LB](#); [Lang, S, et al.](#))
- Risk of Myocardial Infarction with Exposure to Specific ARV from the PI, NNRTI, and NRTI Drug Classes: The D:A:D Study ([Abstract 44LB](#); [Lundgren, J, et al.](#))
- Simplification with Fixed-dose Tenofovir/Emtricitabine or Abacavir/Lamivudine in Adults with Suppressed HIV Replication: The STEAL Study, a Randomized, Open-label, 96-Week, Non-inferiority Trial ([Abstract 576](#); [Cooper, D, et al.](#))
- No Association of Abacavir Use with Risk of Myocardial Infarction or Severe Cardiovascular Disease Events: Results from ACTG A5001 ([Abstract 721](#); [Benson, C, et al.](#))
- Tenofovir and PI Use Are Associated with an Increased Prevalence of Proximal Renal Tubular Dysfunction in the Swiss HIV Cohort Study ([Abstract 743](#); [Fux, C, et al.](#))
- Rosiglitazone Improves Lipotrophy in Patients Receiving Thymidine-sparing Regimens ([Abstract 42LB](#); [El Bejjani, D, et al.](#))

Co-morbid Conditions and Complications of HIV

- Review of Cancer Incidence in Raltegravir Clinical Trials ([Abstract R-106](#); [Cooper, D, et al.](#))
- Relationship between current level of Immunodeficiency and non-AIDS-defining Malignancies ([Abstract 860a](#); [Reekie J, et al.](#))
- Prognosis of non-Hodgkin's Lymphoma in HIV-infected Patients ([Abstract 871](#); [Chao, C, et al.](#))
- Factors Associated with Mortality in the Study of Fat Redistribution and Metabolic Change in HIV Infection ([Abstract 706](#); [Modrich L, et al.](#))
- Initiating ART during TB Treatment Significantly Increases Survival: Results of a Randomized Controlled Clinical Trial in TB/HIV-co-infected Patients in South Africa ([Abstract 36a](#); [Karim, SA, et al.](#))

Hepatitis and other Opportunistic Infections

- High HCV Is Associated with an Increased Risk for Mortality in HIV/HCV-co-infected Individuals ([Abstract 101](#); [Rockstroh, J, et al.](#))
- Survival of HIV/HCV-co-infected Patients with Compensated Liver Cirrhosis: Effect of HCV Therapy ([Abstract 106](#); [Montes, ML, et al.](#))
- SLAM-C (ACTG A5178): Role of Early Virologic Response in Extended Therapy with PEG-Interferon and Weight-Based Ribavirin in HCV/HIV Co-infection ([Abstract 103LB](#); [Chung, R, et al.](#))
- Predictors of Chronic HBV Infection in HIV-infected Individuals ([Abstract 812](#); [Landrum, M, et al.](#))
- HBV Blippers and Rebounders under Treatment with Tenofovir in HIV/HBV Co-infection ([Abstract 100](#); [Lacombe, K, et al.](#))
- HDV Infection Impairs Health-related Quality of Life of Patients Co-infected with HIV and HBV ([Abstract 819](#); [Lacombe, K, et al.](#))

Drug Interactions

- Abacavir Use Is Not Associated with Lack of Virologic Response in ARV-treated HIV/HCV-co-infected Patients Receiving Pegylated Interferon and Ribavirin ([Abstract 850](#); [Amorosa, V, et al.](#))
- Pharmacokinetics and Safety of Twice-daily Atazanavir (300 mg) and Raltegravir (400 mg) in Healthy Subjects ([Abstract 696](#); [Zhu, L, et al.](#))



The complete collection of previous issues of HIV CareLink are available online.

To view past issues, please visit the archives at:

www.FCAETC.org/Newsletter